Get the weekly note
ETFIQetfiq.com · independent ETF data

Data as of .

BBP vs GNOM: which is really different?

BBP and GNOM hold 16% of their weight in the same names, and GNOM returned more over the year.

Virtus Biotech ETF and Global X Genomics & Biotechnology ETF.

12.4%BBP in the S&P 500
20.9%GNOM in the S&P 500
+47.5%BBP total return, 1 year
+77.5%GNOM total return, 1 year

ETFIQ Off-Index Score: BBP scores higher

How much of it is not the index it is sold as an alternative to?

BBP 61.7GNOM 44.50.1, the lowest in this set91.8, the highest

A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed

BBP88% of its weight is outside the S&P 500 · 1 year to Sep 18, 2026
12%88%inof its weight outside the S&P 500active share 99% · top ten 26% of the fund · 60 holdings filed Apr 30, 2026 · Nasdaq-100: 9% in12%88%inof its weight outside the S&P 500active share 99% · top ten 26% of the fund
GNOM79% of its weight is outside the S&P 500 · 1 year to Sep 18, 2026
21%79%in the S&P 500of its weight outside the S&P 500active share 98% · top ten 53% of the fund · 52 holdings filed Sep 18, 2026 · Nasdaq-100: 5% in21%79%inoutside the S&P 500active share 98% · top ten 53% of the fund

16% of the two portfolios are the same securities at the same weight.

What they hold in common

By the books each fund has filed, BBP and GNOM hold 16% of their money in the same securities at the same weight.

Positions BBP and GNOM both hold, largest shared weight first
HoldingBBPGNOM
MODERNA INC2.50%7.99%
BIONTECH SE1.75%2.55%
LEGEND BIOTECH CORP1.69%1.96%
ARROWHEAD PHARMACEUTICALS INC1.68%2.59%
GILEAD SCIENCES INC1.74%1.63%
BIOMARIN PHARMACEUTICAL INC1.62%3.41%
VERTEX PHARMACEUTICALS INC1.52%3.35%
SAREPTA THERAPEUTICS INC1.55%1.51%
CRISPR THERAPEUTICS AG1.48%2.89%
ULTRAGENYX PHARMACEUTICAL IN1.09%1.02%
Only in each
Only in BBPOnly in GNOM
IMMUNITYBIO INC 4.83%TWIST BIOSCIENCE CORP 7.40%
APELLIS PHARMACEUTICALS INC 2.60%10X GENOMICS INC-CLASS A 6.53%
KALVISTA PHARMACEUTICALS INC 2.53%GUARDANT HEALTH INC 5.78%
IOVANCE BIOTHERAPEUTICS INC 2.45%ILLUMINA INC 5.30%
MIRUM PHARMACEUTICALS INC 2.40%NATERA INC 5.13%
AXSOME THERAPEUTICS INC 2.25%GENSCRIPT BIOTECH CORP 4.29%
KINIKSA PHARMACEUTICALS INTERNATIONAL PL 2.07%BIO-TECHNE CORP 3.56%
ROIVANT SCIENCES LTD 2.07%QIAGEN N.V. 3.13%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Sep 18, 2026.

Performance, window by window

BBP and GNOM over each window. Every figure is an ETFIQ calculation with distributions reinvested. Source: ETFIQ.
WindowTotal returnvs the S&P 500vs the Nasdaq-100
BBPGNOMBBPGNOMBBPGNOM
3 months+15.3%+27.6%+13.1 pts+25.4 pts+17.8 pts+30.1 pts
6 months+29.5%+56.4%+11.5 pts+38.4 pts+5.3 pts+32.2 pts
1 year+47.5%+77.5%+30.9 pts+60.9 pts+25.7 pts+55.7 pts
3 years+103.0%+59.3%+24.6 pts−19.1 pts+4.8 pts−38.9 pts
Since launch+304.4%+9.8%−56.6 pts−185.2 pts−371.1 pts−297.4 pts
Open the live comparison on ETFIQ
BBP and GNOM on the same fields, as of Sep 18, 2026. Source: ETFIQ.
BBP
Virtus Biotech ETF
Holds 60 stocks in biotech, 12% of its weight in S&P 500 companies
GNOM
Global X Genomics & Biotechnology ETF
Holds 52 stocks in genomics and gene editing, 21% of its weight in S&P 500 companies
IssuerVirtusGlobal X
ThemeBiotechGenomics and gene editing
In the S&P 50012.4%20.9%
Active share vs the S&P 50099.0%97.6%
In the Nasdaq-1008.9%5.0%
Holdings6052
Top ten, share of the fund25.7%52.7%
Expense ratio0.34%0.50%
Fee for the differing part0.34%0.51%
Total return, 1 year+47.5%+77.5%
vs the S&P 500+30.9 pts+60.9 pts
vs the Nasdaq-100+25.7 pts+55.7 pts
Below its high−5.5%−39.6%
Net assets$59m$100m

BBP in plain words

By weight, 12% of BBP's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 26% of the fund across 60 positions, as filed for Apr 30, 2026. Over the year to Sep 18, 2026 the fund returned +47.5% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 30.9 pts. It sits 5.5% below its all-time high of Aug 19, 2026.

GNOM in plain words

By weight, 21% of GNOM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 53% of the fund across 52 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +77.5% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 60.9 pts. It sits 39.6% below its all-time high of Feb 8, 2021.

Questions people ask

Do BBP and GNOM hold the same stocks?
By their latest filings, 16% of their books are the same securities at the same weight, which is mostly different names. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, BBP or GNOM?
BBP has 12% of its weight in S&P 500 names and GNOM has 21%, so BBP differs more from the index.
Which is cheaper, BBP or GNOM?
BBP charges 0.34% a year and GNOM charges 0.50%, so BBP is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

BBP against GNOM, ETFIQ, data as of Sep 18, 2026. Every figure is calculated from a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, BBP against GNOM, data as of Sep 18, 2026. https://etfiq.com/compare/themes/bbp-vs-gnom Free to use with attribution; the underlying files are at Open data.

How every figure is computed · Standards and sources